Slovak-founded Sensible Biotechnologies has secured $47 million to advance its cell-based mRNA platform, scale manufacturing in Europe, and develop new applications across cancer, genetic diseases, and biosecurity.
Superseding our biology is the key challenge that humanity faces. Sumon Sadhu maps out the next 30 years, from living through AGI to a future where medicine is a program you write and nature’s defaults become our decisions.
Founded by investors with backgrounds in Wall Street biotech research and healthcare finance, Kos aims to give European life sciences companies greater access to US industry expertise, capital, and networks.
Next on The Recursive podcast, we welcome Xavier Macenac, a seasoned French businessman whose entrepreneurial journey is deeply intertwined with the fast development of the Bulgarian post-communist economy. Xavier Marcenac first came to Bulgaria in the early 90s. One of his early jobs back then was doing audits and...
